Sight offers an AI‑driven platform that captures real‑time imaging and functional profiling of live immune cells, converting cellular behavior into quantitative immune signatures. These AI‑generated biomarkers provide pharmaceutical, biotech, and research organizations with reproducible data for faster target validation, precise patient stratification, and accelerated therapeutic development.
Funding
Funding not disclosed
Founders
Product
Problem
Immunology research and therapeutic development often lack high‑resolution, functional data on live immune cells, making it difficult to identify reliable biomarkers for drug discovery and patient stratification.
Solution
Sight provides an AI‑driven platform that captures and analyzes live immune cells in real time to generate detailed immune signatures. Proprietary datasets combined with advanced machine‑learning models translate cellular behavior into actionable biomarkers. These signatures offer researchers and developers deeper clinical insights, enabling faster target validation, more precise patient selection, and accelerated therapeutic development. The platform delivers standardized, reproducible data that can be integrated into existing discovery pipelines and clinical studies.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as academic and contract research organizations focused on immunology research and therapeutic development.
Features
- Real‑time imaging and profiling of live immune cells to capture functional dynamics
- Proprietary AI algorithms that decode cellular interactions into quantitative immune signatures
- Curated, high‑quality datasets that are exclusive to Sight’s platform
- Automated biomarker generation pipelines for rapid hypothesis testing
- Integration tools for exporting signatures into common bioinformatics and clinical workflows